Paradoxical Results after Inadvertent Use of Cosyntropin [Adrenocorticotropin Hormone (1-24)] Rather than Acthrel (Ovine Corticotropin Releasing Hormone) during Inferior Petrosal Sinus Sampling |
| |
| Institution: | 1. Endocrinology Center and Clinics, Medical College of Wisconsin, Milwaukee, Wisconsin;2. Division of Endocrinology, Metabolism, and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, Wisconsin;3. Division of Endocrinology, Diabetes and Metabolism, Wheaton Franciscan Medical Group, Racine, Wisconsin;4. University of Texas Southwestern Medical School; Dallas, Texas;5. Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan;6. Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, Ohio.;1. Eli Lilly and Company, Indianapolis, Indiana;2. Biogen Idec, Weston, Massachusetts;3. School of Graduate Entry Medicine, University of Nottingham, Nottingham, United Kingdom;4. Keck School of Medicine, University of Southern California, Los Angeles, California;5. Endocrine Clinic of Southeast Texas, Beaumont, Texas;6. Lilly USA, LLC, Indianapolis, Indiana.;1. Departments of Endocrinology;2. Pathology & Laboratory Medicine, Brody School of Medicine at East Carolina University, Greenville, North Carolina.;1. Department of Endocrinology, Diabetes and Metabolism, Endocrinology and Metabolism Institute, Cleveland Clinic Foundation, Cleveland, Ohio;2. Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, Oregon;3. Department of Medicine, VA Palo Alto Health Care Service and Stanford University School of Medicine, Palo Alto, California. |
| |
| Abstract: | ObjectiveThe use of ovine corticotropin releasing hormone (oCRH) maximizes the diagnostic accuracy of inferior petrosal sinus sampling (IPSS) in patients with adrenocorticotropin hormone (ACTH)-dependent Cushing’s syndrome (CS). oCRH is marketed as ACTHrel and, understandably, may be confused with cosyntropin ACTH (1-24)]. The inadvertent substitution of synthetic ACTH(1-24) for oCRH (ACTHrel) during IPSS may cause unexpected and misleading results. The aim of this report is to raise awareness of the potential confounding results created when synthetic ACTH(1-24) is mistakenly used during IPSS.MethodsWe present 3 patients treated at 3 different centers with ACTH-dependent CS in whom ACTH(1-24) was mistakenly substituted for oCRH (ACTHrel) during IPSS.ResultsIn all patients, there was an abrupt and unexpected decrease in plasma ACTH in the inferior petrosal sinus (IPS) samples after presumptive stimulation with oCRH. Re-evaluation of the patients’ pharmacy records confirmed that synthetic ACTH(1-24) had been used rather than oCRH during each procedure. Because “sandwich” immunometric assays for ACTH measure the entire pool of endogenous ACTH, the administration of synthetic ACTH(1-24) artifactually decreases the endogenous plasma ACTH(1-39) measurement by binding only to the N-terminal antibody raised against ACTH(1-17) and not to the C-terminal antibody raised against ACTH(34-39). This results in a lack of a detectable sandwich complex and explains the apparent reduction in ACTH concentration.ConclusionAn abrupt decrease in ACTH during IPSS suggests that synthetic ACTH(1-24) rather than oCRH (ACTHrel) has been administered. The labeling of oCRH as ACTHrel poses a potential patient safety problem about which endocrinologists, interventional radiologists, and pharmacists should be aware. (Endocr Pract. 2014;20: 646-649) |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
